BIOTECH ASSISTANT / FIELD NOTES

Quantoom and Inside Therapeutics connect RNA production with LNP formulation

Company / institutional announcement · Quantoom Biosciences

Source published: 2026-08-25 · Event / reporting date: 2026-08-24

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Quantoom Biosciences and Inside Therapeutics announced a nonexclusive commercial collaboration connecting Ntensify Micro and Mini RNA production with TAMARA lipid nanoparticle formulation. Activities include customer referrals, coordinated marketing, and shared events, while both businesses continue operating and selling independently. The agreement concerns research workflows and commercial coordination, rather than demonstrating a jointly validated, end-to-end GMP manufacturing process.

Why it may matter

Closer coordination between RNA synthesis and formulation suppliers may simplify research workflows, but individual programs still require process compatibility and performance testing.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP Formulation Development & Manufacturing

Related updates

2026-11-06Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNP Ask AI ↗

2026-11-05Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-04Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNP Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗